标题
Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors
作者
关键词
-
出版物
CLINICAL PHARMACOKINETICS
Volume -, Issue -, Pages -
出版商
Springer Nature
发表日期
2019-02-28
DOI
10.1007/s40262-019-00748-2
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Correlation between nivolumab exposure and treatment outcomes in non–small-cell lung cancer
- (2019) Edwin A. Basak et al. EUROPEAN JOURNAL OF CANCER
- Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
- (2018) Roberta Zappasodi et al. CANCER CELL
- A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
- (2018) Xuexiang Du et al. CELL RESEARCH
- Pembrolizumab exposure-response assessments challenged by association of cancer cachexia and catabolic clearance
- (2018) David Turner et al. CLINICAL CANCER RESEARCH
- Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy
- (2018) Benjamin Ribba et al. CLINICAL CANCER RESEARCH
- The Long Neglected Player: Modeling Tumor Uptake to Guide Optimal Dosing
- (2018) Leire Ruiz-Cerdá et al. CLINICAL CANCER RESEARCH
- Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status
- (2018) Paul G. Baverel et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Next generation of immune checkpoint therapy in cancer: new developments and challenges
- (2018) Julian A. Marin-Acevedo et al. Journal of Hematology & Oncology
- Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
- (2018) Fei Tang et al. Cell and Bioscience
- Systems Pharmacology: Defining the Interactions of Drug Combinations
- (2018) J.G. Coen van Hasselt et al. Annual Review of Pharmacology and Toxicology
- Tumor drug penetration measurements could be the neglected piece of the personalized cancer treatment puzzle
- (2018) Imke H. Bartelink et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Time Is Money: Optimizing the Scheduling of Nivolumab
- (2018) Mark J. Ratain et al. JOURNAL OF CLINICAL ONCOLOGY
- Immuno-Oncology: Emerging Targets and Combination Therapies
- (2018) Henry T. Marshall et al. Frontiers in Oncology
- Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
- (2017) Andrea B. Apolo et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of saturable distribution in compartmental PK models: dynamics and practical use
- (2017) Lambertus A. Peletier et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response
- (2017) Hongshan Li et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial
- (2017) James L Gulley et al. LANCET ONCOLOGY
- Fixed Dosing of Monoclonal Antibodies in Oncology
- (2017) Jeroen J.M.A. Hendrikx et al. ONCOLOGIST
- Antibody Isotypes for Tumor Immunotherapy
- (2017) Anna Kretschmer et al. TRANSFUSION MEDICINE AND HEMOTHERAPY
- Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
- (2017) Guillermo De Velasco et al. Cancer Immunology Research
- Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
- (2017) Thomas Powles et al. JAMA Oncology
- Evaluation of dosing strategy for pembrolizumab for oncology indications
- (2017) Tomoko Freshwater et al. Journal for ImmunoTherapy of Cancer
- Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody
- (2017) Renee N. Donahue et al. Journal for ImmunoTherapy of Cancer
- Ipilimumab safety profile: Summary of findings from completed trials in advanced melanoma.
- (2017) R. A. Ibrahim et al. JOURNAL OF CLINICAL ONCOLOGY
- FOCUS 3: A study to determine the feasibility of molecular selection of therapy using K-RAS, B-RAF, and topo-1 in patients with advanced colorectal cancer (ACRC).
- (2017) Tim Maughan et al. JOURNAL OF CLINICAL ONCOLOGY
- A simple and rapid LC-MS/MS method for therapeutic drug monitoring of cetuximab: a GPCO-UNICANCER proof of concept study in head-and-neck cancer patients
- (2017) François Becher et al. Scientific Reports
- CTLA-4 and PD-1 Pathways
- (2016) Elizabeth I. Buchbinder et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer
- (2016) M. Chatterjee et al. ANNALS OF ONCOLOGY
- Influence of immunoglobulin isotype on therapeutic antibody function
- (2016) Stephen A. Beers et al. BLOOD
- Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients
- (2016) Morgane Caulet et al. CLINICAL PHARMACOKINETICS
- Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non–Small Cell Lung Cancer Patients Treated with Anti–PD-1/PD-L1 Antibodies
- (2016) Takehito Shukuya et al. Journal of Thoracic Oncology
- Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
- (2016) Howard L Kaufman et al. LANCET ONCOLOGY
- Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
- (2016) Celine Boutros et al. Nature Reviews Clinical Oncology
- Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges
- (2016) Emilie M.J. van Brummelen et al. ONCOLOGIST
- Understanding cachexia as a cancer metabolism syndrome
- (2016) P E Porporato Oncogenesis
- Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy
- (2016) Shruti Agrawal et al. Journal for ImmunoTherapy of Cancer
- RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial
- (2015) J. L. Lee et al. ANNALS OF ONCOLOGY
- Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
- (2015) Anne Bertrand et al. BMC Medicine
- Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
- (2015) A. Patnaik et al. CLINICAL CANCER RESEARCH
- Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: Translating TNF-α experience to oncology
- (2015) TH Oude Munnink et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab
- (2015) Zeynep Eroglu et al. EUROPEAN JOURNAL OF CANCER
- Checkpoint inhibitors in Hodgkin's lymphoma
- (2015) Barbara Jezeršek Novaković EUROPEAN JOURNAL OF HAEMATOLOGY
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- (2015) Antoni Ribas et al. LANCET ONCOLOGY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Optimizing Oncology Therapeutics Through Quantitative Translational and Clinical Pharmacology: Challenges and Opportunities
- (2015) K Venkatakrishnan et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma
- (2014) Yan Feng et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer
- (2014) Kayoko Waki et al. CANCER SCIENCE
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Complement Activation Plays a Key Role in Antibody-Induced Infusion Toxicity in Monkeys and Rats
- (2014) T. Tawara et al. JOURNAL OF IMMUNOLOGY
- Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate-associated neutropenia
- (2013) J. G. Coen van Hasselt et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Exposure-Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma
- (2013) Y. Feng et al. CLINICAL CANCER RESEARCH
- The Clinical Viewpoint: Definitions, Limitations of RECIST, Practical Considerations of Measurement
- (2013) L. C. Villaruz et al. CLINICAL CANCER RESEARCH
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
- (2013) Tyler R. Simpson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
- (2013) Andrew M. Intlekofer et al. JOURNAL OF LEUKOCYTE BIOLOGY
- PD-1 Expression on Peripheral Blood Cells Increases with Stage in Renal Cell Carcinoma Patients and Is Rapidly Reduced after Surgical Tumor Resection
- (2013) A. W. MacFarlane et al. Cancer Immunology Research
- Evolution of end points for cancer immunotherapy trials
- (2012) A. Hoos ANNALS OF ONCOLOGY
- Optimizing drug development of anti-cancer drugs in children using modelling and simulation
- (2012) Johan G.C. van Hasselt et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Application of knockout mouse models to investigate the influence of FcγR on the tissue distribution and elimination of 8C2, a murine IgG1 monoclonal antibody
- (2012) Lubna Abuqayyas et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Superior In vivo Efficacy of Afucosylated Trastuzumab in the Treatment of HER2-Amplified Breast Cancer
- (2010) Teemu T. Junttila et al. CANCER RESEARCH
- Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
- (2010) Ron J. Keizer et al. CLINICAL PHARMACOKINETICS
- Improved Endpoints for Cancer Immunotherapy Trials
- (2010) A. Hoos et al. JNCI-Journal of the National Cancer Institute
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic–pharmacodynamic modeling of biologics
- (2009) Leonid Gibiansky et al. Expert Opinion on Drug Metabolism & Toxicology
- Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage
- (2009) Tanja Schneider-Merck et al. JOURNAL OF IMMUNOLOGY
- Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
- (2008) W Wang et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now